Secukinumab: Long-term Safety and Efficacy in Psoriasis

REFERENCES

1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-12.
2. Radtke MA, Schafer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151-7.
3. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-94.
4. Lebwohl M. Treatment of skin disease : comprehensive therapeutic strategies. 2nd ed. Philadelphia, Pa.: Mosby/Elsevier; 2006. xxiv, 723 p. p.
5. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-5.
6. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-9.
7. Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, et al. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2016. AQ: Complete reference, volume, page numbers.
8. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2(4):525-37.
9. Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7(6):481-8.
10. Singh SM, Narang T, Dogra S, Verma AK, Gupta S, Handa S. An analysis of dermatological quality-of-life scores in relation to psychiatric morbidity in psoriasis. Indian Dermatol Online J. 2016;7(3):208-9.
11. Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155-7.
12. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993-1005.
13. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596-610.
14. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413-20.
15. Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb). 2014;4(1):1-9.
16. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38.
17. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039-46.
18. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-11.
19. Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777-87.
20. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
21. Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9 e9.
22. Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36 e1.
23. Bissonnette R LT, Thaçi D, Toth D, Messina I, Xia S, Safi J, Piketty C, Papavassilis C, Mrowietz U. Secukinumab demonstrates favorable safety in subjects with moderate to severe psoriasis: 3 year results from an extension to the SCULPTURE study. Poster presented at: 25th European Academy of Dermatology and Venereology Congress, 28th September - 2nd October 2016, Vienna, Austria.
24. Bissonnette R LT, Diamant T, Toth D, Letzelter K, Xia S, Mazur R, Milutinovic M, Leonardi C. Secukinumab Demonstrates Sustained High Efficacy and a Favorable Safety Profile in Moderate to Severe Psoriasis Patients Through 4 Years of Treatment. Oral presentation at: 25th European Academy of Dermatology and Venereology Congress, 28th September – 2nd October 2016, Vienna, Austria.
25. Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016.
26. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271-5.
27. Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You RQ, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80.
28. Gottlieb A SJ, Kubanov A, Tao A, Regnault P, Fox T, Milutinovic M, Frueh J. Secukinumab is Effective in Subjects With Moderate to Severe Palmoplantar Psoriasis: 1.5 Year Results From the GESTURE Study. Poster presented at: 25th European Academy of Dermatology and Venereology Congress, 28th September – 2nd October 2016, Vienna, Austria.
29. Augustin M, Reich K, Blome C, Schafer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580-5.
30. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317-21.
31. Choi JW, Kim BR, Seo E, Youn SW. Identification of nail features associated with psoriasis severity. J Dermatol. 2016.
32. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300-3.
33. Reich K SJ, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M. Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from the TRANSFIGURE Study. Poster presented at: 25th European Academy of Dermatology and Venereology Congress, 28th September – 2nd October 2016, Vienna, Austria.
34. McInnes IB KB, Mease P, Bhosekar V, Mpofu S, Gandhi K, Gaillez C on behalf of the FUTURE 2 study group. Secukinumab Provides Rapid and Sustained Reductions in Dactylitis, Enthesitis and Nail Psoriasis in Patients with Psoriatic Arthritis: 52-week Results of the FUTURE 2 study. Poster presented at: 25th European Academy of Dermatology and Venereology Congress, 28th September – 2nd October 2016, Vienna, Austria.
35. Cosentyx [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2016.

AUTHOR CORRESPONDENCE